What is the effect of cs/bDMARDs on weight in #PsA? ⬇️Weight loss seen with: IL17i IL23i csDMARDs ⬆️Weight gain seen with: TNFi IL12/23i Important to consider #comorbidity & #BMI in management decisions in PsA Ab2639 #ACR24 @RheumNow

A#2582 McInnes Sonelokimab - IL17A,F nanobody Prior P2 in PsO, HS ARGO: P2 W24 RCT Significant improv in ACR response High PASI90/100 data Up to 60% achieved MDA by W24 Improved PsAID domains (PRO) Safety no IBD, MACE, depr. 2% oral candida IZAR-1,2 - P3 ongoing #ACR24 @RheumNow https://t.co/O4fEhTC8jK

• https://x.com/ericdeinmd/status/1858577759452180634/photo/1
• https://x.com/ericdeinmd/status/1858577759452180634/photo/1

SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi

• https://x.com/RHEUMarampa/status/1858580860238217419/photo/1

A#2583 Apremilast for axial inflamm in PsA, assess by CANDEN MRI scoring MOSAIC P4 open label trial Reduction in inflammation seen in vertebral bodies & posteriolateral, not in facet joints No changes in SPARCC SIJ, spine - though low baseline SIJ inflammation @RheumNow #ACR24 https://t.co/3GKEGJbtdc

• https://x.com/ericdeinmd/status/1858581617067127217/photo/1

A#2584 Mease Zasocitinib TAK-279 - potent, selective TYK2i P2b, 12w PsA RCT 15/30 mg - similar response, better than PBO for ACR20/50/70, MDA, DAPSA, PASDAS 29% MDA v 13% PBO Safety no signal for MACE, cancer, serious ifn, death. Mild acne signal noted @RheumNow #ACR24 https://t.co/1eqD9R5fLe

• https://x.com/ericdeinmd/status/1858584654712017059/photo/1
• https://x.com/ericdeinmd/status/1858584654712017059/photo/1

Selective TYK2i zasocitinib, results of Phase 2 DBRCT Dose dependent improvements in various PsA outcomes; NNT~5 for DAS28 remission, NNT~20 for PASDAS Hard to compare to current agents, somewhere between JAKs (woot!) & "apremlist zone" 🫣 #ACR24 @RheumNow Abstr#2584 #ACRbest https://t.co/t0y6C618ll

• https://x.com/EBRheum/status/1858585213095604473/photo/1

A#2585 PsABIOnd observ cohort study of IL23 (GUS) or IL17i 6 mo interim results of 686 pts PROs: PsAID-12 High Rx persistence at 6mo -94% on both Rx Comparable improvement in PsAID-12 - best results skin, discomfort 1/2 with clinically meaningful improvement #ACR24 @RheumNow https://t.co/TM1jwTRR7C

• https://x.com/ericdeinmd/status/1858589439746068566/photo/1
• https://x.com/ericdeinmd/status/1858589439746068566/photo/1
• https://x.com/ericdeinmd/status/1858589439746068566/photo/1

A#2586 EBIO study - secukinumab on entheseal bx in PsA. Compare b/l to 3+ mo on SEC Biopsy: change of entheseal cell composition on IL-17A Rx - decr Il-17A producing cells in responding pts Spatial transcriptomics - colocalizarjon of ILC2, CD200+ fibroblasts @RheumNow #ACR24 https://t.co/kMiqpBRxuE

• https://x.com/ericdeinmd/status/1858593064912028040/photo/1

Walsh et al. Direct mailing of PEST questionnaire to psoriasis patients. 13% PEST+, 4% seen by rheum (to date). 75% deemed appropriate for rheum to see - breakdown in picture. @RheumNow #ACR24 Abstr#2635 https://t.co/vlGJ977SV7 https://t.co/dbDUpwDZxy

• Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis:…
• https://x.com/RichardPAConway/status/1858602829146960258/photo/1